Dolutegravir and Folic Acid Interaction during Neural System Development in Zebrafish Embryos.
Daniela ZizioliEugenia Quiros-RoldanSara FerrettiLuca MignaniGiorgio TieccoEugenio MontiFrancesco CastelliIsabella ZanellaPublished in: International journal of molecular sciences (2024)
Dolutegravir (DTG) is one of the most prescribed antiretroviral drugs for treating people with HIV infection, including women of child-bearing potential or pregnant. Nonetheless, neuropsychiatric symptoms are frequently reported. Early reports suggested that, probably in relation to folic acid (FA) shortage, DTG may induce neural tube defects in infants born to women taking the drug during pregnancy. Subsequent reports did not definitively confirm these findings. Recent studies in animal models have highlighted the association between DTG exposure in utero and congenital anomalies, and an increased risk of neurologic abnormalities in children exposed during in utero life has been reported. Underlying mechanisms for DTG-related neurologic symptoms and congenital anomalies are not fully understood. We aimed to deepen our knowledge on the neurodevelopmental effects of DTG exposure and further explore the protective role of FA by the use of zebrafish embryos. We treated embryos at 4 and up to 144 h post fertilization (hpf) with a subtherapeutic DTG concentration (1 μM) and observed the disruption of the anterior-posterior axis and several morphological malformations in the developing brain that were both prevented by pre-exposure (2 hpf) and rescued by post-exposure (10 hpf) with FA. By whole-mount in situ hybridization with riboprobes for genes that are crucial during the early phases of neurodevelopment ( ntl , pax2a , ngn1 , neurod1 ) and by in vivo visualization of the transgenic Tg( ngn1 :EGFP) zebrafish line, we found that DTG induced severe neurodevelopmental defects over time in most regions of the nervous system (notochord, midbrain-hindbrain boundary, eye, forebrain, midbrain, hindbrain, spinal cord) that were mostly but not completely rescued by FA supplementation. Of note, we observed the disruption of ngn1 expression in the dopaminergic regions of the developing forebrain, spinal cord neurons and spinal motor neuron projections, with the depletion of the tyrosine hydroxylase (TH) + dopaminergic neurons of the dorsal diencephalon and the strong reduction in larvae locomotion. Our study further supports previous evidence that DTG can interfere with FA pathways in the developing brain but also provides new insights regarding the mechanisms involved in the increased risk of DTG-associated fetal neurodevelopmental defects and adverse neurologic outcomes in in utero exposed children, suggesting the impairment of dopaminergic pathways.
Keyphrases
- spinal cord
- neuropathic pain
- spinal cord injury
- young adults
- polycystic ovary syndrome
- hiv infected patients
- antiretroviral therapy
- emergency department
- hiv infected
- healthcare
- resting state
- adverse drug
- poor prognosis
- gene expression
- white matter
- endothelial cells
- pregnancy outcomes
- metabolic syndrome
- blood brain barrier
- adipose tissue
- insulin resistance
- early onset
- high glucose
- climate change
- transcription factor
- physical activity
- genome wide
- south africa
- preterm infants
- gestational age
- electronic health record
- breast cancer risk
- cerebral ischemia